Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 3, Issue , 2016, Pages 43-50

  Savica, Rodolfo ^a,b   Murray, Melissa E ^c   Persson, Xuan Mai ^a   Kantarci, Kejal ^a   Parisi, Joseph E ^a   Dickson, Dennis W ^c   Petersen, Ronald C ^a,b   Ferman, Tanis J ^d   Boeve, Bradley F ^a   Mielke, Michelle M ^a,b  

^a MAYO CLINIC   (United States)

^b Division of Epidemiology   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Autopsy; Ceramide; Lewy body; Lipids

Indexed keywords

CERAMIDE; FATTY ACID; MONOHEXOSYLCERAMIDE; SPHINGOLIPID; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ELECTROSPRAY MASS SPECTROMETRY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE;

EID: 84961626573     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.02.005     Document Type: Article

References (28)

1. Savica R., Grossardt B.R., Bower J.H., Boeve B.F., Ahlskog J.E., Rocca W.A. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 2013, 70:1396-1402.
2. Tsuboi Y., Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat Disord 2005, 11(Suppl 1):S47-S51.
3. Mielke M.M., Lyketsos C.G. Lipids and the pathogenesis of Alzheimer's disease: is there a link?. Int Rev Psychiatry 2006, 18:173-186.
4. Ruiperez V., Darios F., Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 2010, 49:420-428.
5. Eckert G.P., Wood W.G., Muller W.E. Lipid membranes and beta-amyloid: a harmful connection. Curr Protein Pept Sci 2010, 11:319-325.
6. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
7. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009, 361:1651-1661.
8. Clark L.N., Kartsaklis L.A., Wolf Gilbert R., Dorado B., Ross B.M., Kisselev S., et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009, 66:578-583.
9. Mielke M.M., Maetzler W., Haughey N.J., Bandaru V.V., Savica R., Deuschl C., et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 2013, 8:e73094.
10. Lee J.T., Xu J., Lee J.M., Ku G., Han X., Yang D.I., et al. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004, 164:123-131.
11. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005, 7:1118-1123.
12. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 2004, 101:2070-2075.
13. Gulbins E., Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003, 22:7070-7077.
14. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003, 278:19777-19783.
15. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005, 280:36815-36823.
16. Mielke M.M., Bandaru V.V., Haughey N.J., Rabins P.V., Lyketsos C.G., Carlson M.C. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010, 31:17-24.
17. Mielke M.M., Bandaru V.V., Xia J., Haughey N.J., Fried L.P., Yasar S., et al. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology 2012, 79:633-641.
18. Mielke M.M., Haughey N.J., Ratnam Bandaru V.V., Schech S., Carrick R., Carlson M.C., et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 2010, 6:378-385.
19. Mielke M.M., Haughey N.J., Bandaru V.V., Weinberg D.D., Darby E., Zaidi N., et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis 2011, 27:259-269.
20. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
21. Fujishiro H., Ferman T.J., Boeve B.F., Smith G.E., Graff-Radford N.R., Uitti R.J., et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008, 67:649-656.
22. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
23. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
24. Diagnostic and Statistical Manual of Mental Disorders: 3rd ed. revised 1987, American Psychiatric Association, American Psychiatric Association, Washington, DC.
25. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997, 18:S1-S2.
26. Mielke M.M., Bandaru V.V., Han D., An Y., Resnick S.M., Ferrucci L., et al. Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species. Aging Cell 2015, 14:1014-1023.
27. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381:800-803.
28. O'Bryant S.E., Gupta V., Henriksen K., Edwards M., Jeromin A., Lista S., et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 2015, 11:549-560.